Department of Clinical Pharmacy, College of Pharmacy, King Saud University, P.O. Box 2454, Riyadh 11451, Saudi Arabia.
Pharmacy Practice Department, King Abdulaziz University, Jeddah 80260, Saudi Arabia.
Int J Environ Res Public Health. 2022 Jan 29;19(3):1567. doi: 10.3390/ijerph19031567.
This study aimed to determine the estimated proportion of contraindications among women taking combined oral contraceptives (COCs) and to assess the risk factors associated with their contraindications. This study was cross-sectional. Reproductive-aged women (18-49 years) on any COCs between 2018 and 2020 were recruited from one obstetrics-gynaecology clinic in a university-affiliated hospital and were included. Contraindications were defined using the World Health Organization (WHO) Medical Eligibility Criteria (MEC) for Contraceptive Use. Data were collected from electronic medical records for all included women, as well as a standardised, pretested, structured survey for one-third of the women. In this cross-sectional study, 380 women using COCs were included. Their mean age was 31.645 ± 7.366 years. Among them, 131 (34.5%) participated via a survey and electronic records, while the other 249 (65.5%) participated via electronic records only. The majority of the participants had a Bachelor's degree (59.0%) and were married (62.1%). The overall estimated proportion of patients with at least one contraindication to COCs according to category 3 (relative contraindications) or 4 (absolute contraindications) was 31.3% (95% CI 26.63-35.99). The most common contraindications observed were controlled hypertension, category 3 (12.1%); major surgery with prolonged immobilisation, category 4 (4.7%); migraine with aura at any age, category 4 (4.2%); breastfeeding from six weeks to less than six months postpartum, category 3 (4.0%); and diabetes mellitus with complications, category 4 (3.2%). Significant factors associated with contraindications to COCs were married women (OR 2.19, 95% CI 1.38-3.46), those aged 35 years or more (OR 2.33, 95% CI 1.49-3.66), and those with one or more live births (OR 2.19, 95% CI 1.38-3.46). Ensuring proper assessment prior to prescribing and considering alternatives suitable for long-term use among women taking an oral contraceptive regularly is recommended.
本研究旨在确定服用复方口服避孕药(COC)的女性中禁忌证的估计比例,并评估与禁忌证相关的危险因素。这是一项横断面研究。我们招募了 2018 年至 2020 年期间在一家大学附属医院妇产科诊所使用任何 COC 的育龄妇女(18-49 岁),并将其纳入研究。禁忌证的定义使用了世界卫生组织(WHO)的避孕方法医学标准(MEC)。从所有纳入的女性的电子病历中收集数据,以及对三分之一女性进行标准化、预测试、结构化调查。在这项横断面研究中,我们纳入了 380 名服用 COC 的女性。她们的平均年龄为 31.645 ± 7.366 岁。其中,131 名(34.5%)通过调查和电子记录参与,而另外 249 名(65.5%)仅通过电子记录参与。大多数参与者拥有学士学位(59.0%)且已婚(62.1%)。根据类别 3(相对禁忌证)或 4(绝对禁忌证),至少有一种 COC 禁忌证的患者总体估计比例为 31.3%(95%CI 26.63-35.99)。观察到的最常见禁忌证是控制良好的高血压,类别 3(12.1%);伴有长时间固定的重大手术,类别 4(4.7%);任何年龄的有先兆偏头痛,类别 4(4.2%);产后 6 周至 6 个月内母乳喂养,类别 3(4.0%);以及伴有并发症的糖尿病,类别 4(3.2%)。与 COC 禁忌证相关的显著因素是已婚女性(OR 2.19,95%CI 1.38-3.46)、年龄 35 岁及以上的女性(OR 2.33,95%CI 1.49-3.66)和有一个或多个活产的女性(OR 2.19,95%CI 1.38-3.46)。建议在开具处方前进行适当的评估,并考虑为定期服用口服避孕药的女性提供适合长期使用的替代方法。